The Medicines Company (MDCO) : Traders are bullish on The Medicines Company (MDCO) as it has outperformed the S&P 500 by a wide margin of 4.33% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 4.2%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.76% in the last 1 week, and is up 2.22% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 0.69% and the 50-Day Moving Average is 3.4%.The 200 Day SMA reached 9.58% The Medicines Company is up 12.88% in the last 3-month period. Year-to-Date the stock performance stands at 3.78%.
The Medicines Company (MDCO) has been rated by 5 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $65 and the lowest price target forecast is $43. The average forecast of all the analysts is $51.6 and the expected standard deviation is $8.65.
For the current week, the company shares have a recommendation consensus of Buy. The Medicines Company (NASDAQ:MDCO): The stock opened at $37.89 and touched an intraday high of $38.8 on Friday. During the day, the stock corrected to an intraday low of $37.06, however, the bulls stepped in and pushed the price higher to close in the green at $38.75 with a gain of 2.30% for the day. The total traded volume for the day was 1,347,794. The stock had closed at $38.75 in the previous trading session.
The Medicines Company is a global biopharmaceutical company. The Companys marketed products are: Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Minocin (minocycline) for injection, Orbactiv (oritavancin), PreveLeak and Recothrom Thrombin topical (Recombinant). The Companys products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development, including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States, cangrelor, IONSYS (fentanyl iontophoretic transdermal system), Raplixa, formerly referred to as Fibrocaps, and RPX-602. The Companys four research and development product candidates include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Company also develops ABP-700, an intravenous anesthetic, which is in Phase I of clinical studies.